Opportunities
Search

Expected Outcome:Project results are expected to contribute to some or all of the following expected outcomes:Integrated single-hazard systems into multi-hazard next generation predictive models to assess cascading effects (e.g., heatwave, floods, droughts, landslides, heavy rain) and interactions across meteorological, geophysical, and technological hazards;Enhanced hazard forecasting and response through research on model integration and platform interoperability;Development of holistic risk and resilience metrics to support multi-hazard prevention strategies, encompassing main physical, economic and social effects;Improvement of analysis models considering evolving vulnerability state, due to cascading and cumulative effects, through numerical simulations and experimental tests, possibly also supported by AI applications;Collected reliable data (same granularity and format) and ways t...

Expected Outcome:Project results are expected to contribute to some or all of the following expected outcomes: Identification and prioritization of climate security scenarios, assessing cascading and compounding risks across multiple sectors;Development and validation of advanced tools, technologies, and data-driven solutions for climate - and environmental - risk forecasting, crisis management, and adaptation, including risk analytical and assessment tools, weather alerts and forecasts;Development and validation of advanced tools and technologies to assess and monitor climate-induced disasters, also providing risk information on adaptation and risk reduction measures;Strengthened engagement with stakeholders, ensuring end-user involvement in defining requirements, testing, and validation of climate security solutions;Development and validation of new risk-management tools, technologies...

Expected Outcome:Project results are expected to contribute to some or all of the following expected outcomes:Accelerated adoption of high-TRL (Technology Readiness Level) disaster risk solutions across diverse sectors;Facilitated integration of innovative technologies into existing disaster prevention, preparedness, response, and recovery frameworks;Promoted collaboration among stakeholders to scale proven solutions and enhance resilience;Addressed barriers to deployment, ensuring accessibility and usability of advanced DRS technologies;Strengthened evidence-based decision-making through demonstration and validation of high-TRL solutions in real-world scenarios; Promoted visibility of civil security research results. Scope:This topic aims to foster the widespread adoption and integration of high-TRL (Technology Readiness Level) disaster risk solutions (DRS) across multiple sectors, enha...

Expected Outcome:Project results are expected to contribute to some or all of the following expected outcomes:Increased understanding of policymakers and relevant security practitioners of the phenomenon of terrorism and lone-actor violence towards citizens in confined places such as schools, in the European context;Terrorist and lone-actor attacks to citizens in confined places such as schools, are prevented in Europe by, e.g., detecting and tackling early signs of isolation and radicalisation, as well as the promotion of a secure and inclusive environment;European schools and other confined places, e.g., places of worship, public administration or other buildings accessible to the public, are provided with state-of-the-art means of ensuring their security;Cooperation between Police Authorities in Europe and relevant staff (in schools, public administration, etc.) is improved. Scope:Cit...

Expected Outcome:Project results are expected to contribute to some or all of the following expected outcomes:Improved detection, localization, characterization and, when applicable, neutralisation, of unmanned vehicles alone or in swarms, involved in trafficking or smuggling activities across external borders, while complying with legal and ethical guidelines;Improved border situational awareness, especially in the context of large-scale movements of people across borders, including from potential instrumentalisation of irregular migration, conflicts, social, economic, environmental and climate stress;Better safeguard and promotion of fundamental rights thanks to enhanced situational awareness;Reliable, redundant detection and reaction capacities without putting staff and society at risk. Scope:Capabilities for situational awareness and surveillance of land and sea borders need improvem...

Expected Outcome:Project results are expected to contribute to some or all of the following expected outcomes:Improved protection of minors, including by more reliable age assessments and by minimising the use of intrusive age assessment methods;Improved adaptation, preparedness and cooperation of authorities in the fight against human trafficking;Expanded European-based knowledge on reliability, accuracy and effectiveness of age assessment methods. Scope:Many unaccompanied children and young persons arriving at the external EU borders and seeking asylum, lack official documents showing their identity and age. Age assessment methods are important as they contribute to the determination of, for example, where an individual will be initially housed and what services, supports, and legal processes they will receive to ensure protection and, if applicable, child protection.In other cases, mi...

Expected Outcome:Project results are expected to contribute to some or all of the following outcomes:Critical infrastructure operators and authorities have access to efficient, adaptable, resilient and reliable tools and processes enabling or improving virtual and physical stress tests of their respective assets/ and operations;Critical entities have broader and deeper understanding of their technical and operational vulnerabilities and adaptive capabilities, improving the scenario building and stress tests exercises;Systems allowing notification and collaboration under stress conditions are available for relevant stakeholders;Critical entities are better equipped for post-incident investigations, including data collection, analysis and improved learning, management and sharing in a secure manner;Improved operational procedures including incidents management and training curricula are de...

Expected Outcome:Project results are expected to contribute to some or all of the following outcomes:Identification and analysis of potential new security risks related to innovative technologies being deployed in the urban and peri-urban environments;Innovative and modern tools to identify and measure changes in urban and peri-urban areas caused by the green transition, insofar as they concern security and possible resilience approaches;Verification of measures countering potential safety and security risks, hazards and challenges arising in areas hosting green technologies;Contribution to building awareness and societal acceptance for the safety and security aspects of the green transition;Impacts of incidents involving new and emerging technologies are examined, including environmental and climate risks;Security, safety and resilience aspects of the supply chains of green technologies...

Expected Outcome:Project results are expected to contribute to all of the following expected outcomes:Increased understanding of European policy makers, research community, biotech companies, and relevant security practitioners of the threat of bioterrorism and of synthetic biology, including a thorough lawful analysis of what needs to be monitored in this context, what needs to be regulated and how;Awareness raised within the related scientific community how research in synthetic biology can be used for malicious purposes. Scope:The rising threat of bioterrorism is driven by recent scientific advancements, notably by growing accessibility of synthetic biology, genetic engineering, related commercial services and public databases, which in turn enhance their obtainability to non-state actors and individuals with malicious intentions. The proliferation of do-it-yourself biohacking and com...

Expected Outcome:Project results are expected to contribute to some or all of the following expected outcomes:Development of innovative tools and methodologies to monitor and improve risk awareness across society, integrating diverse community perspectives and leveraging advanced technologies;Development and uptake solutions and tools for the successful increase of safety culture and societal resilience of communities with concrete material, while considering also the inclusion and protection of marginalized populations in disaster scenarios;Creation of comprehensive, inclusive preparedness plans that involve all societal sectors and governance levels, ensuring coordinated and effective responses to disasters (such as from early warning to early action), including scarcity of resources;Establishment of a resilient, adaptive response framework that enhances collaboration between public au...

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.   Distinctive Features: ·       For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details. ·       Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. ·       Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas. Distinctive Features: ·        If developing new drugs or device(s), the research team must include expertise in the regulatory approval process. ·        The TRA includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. ·        Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel and Post-Award Transition Plan. ·        Programmatic review criteria include adherence to the intent of the TRA, contribution to the VRP portfolio, relative impact and relevance to military health. ·        The VRP may share FY26 TRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials. Distinctive Features: ·        The IIRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels. ·        Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI. ·        Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel. ·        Programmatic review criteria include adherence to the intent of the IIRA, contribution to the VRP portfolio, relative impact, and relevance to military health. ·        The VRP may share FY26 IIRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI).Distinctive Features: This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners (e.g., SCI Lived-Experience Consultants, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA) supports translational research that will accelerate the movement of promising ideas in spinal cord injury (SCI) research into clinical applications.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.• Applications to this funding opportunity must name at least one SCI community partner (e.g., SCI Lived-Experience Consultant, representative of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) supports high-impact, new, or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot, or optimization, to prepare for future larger-scale clinical trials or implementation. Primary objectives of this mechanism include:• Accelerating the translation of current and emerging techniques or interventions into clinical use by addressing specific barrier(s) to clinical success for the purpose of de-risking or informing the design of definitive trials.• Identifying the most effective diagnosis, treatment and rehabilitation options to support critical decision-making for patients, clinicians, care partners and policymakers.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.• Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners who will provide advice and consultation throughout the planning and implementation of the research project.

Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA) supports studies that have the potential to make an important contribution to spinal cord injury (SCI) research, patient care and/or quality of life. May focus on any phase of research from basic through translational science, though studies that focus solely on identifying intervention targets are discouraged.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Expected Impact:FOR ALL THREE THEMATIC PRIORITIES:Expected impact at the closure of the project (non-exhaustive list): Innovative technologies tested and adopted by the market;Innovative solutions deployed improving businesses confidence, competences and means to digitalise and grow; Contribution to digitisation and health systems transformation, through various types of innovation and the supply of IT services;Uptake of technologically/economically reliable and viable solutions on the market;Deployment of new technologies fostering the growth of Europe’s manufacturing sector;Innovative technologies adopted by SMEs;Identification of possible sources of funding/funding mix, to cover the residual investment needs (public-private partnerships for the deployment of innovation, the collaboration with venture capitals, EIB group loans etc);Strengthening innovation diffusion channels;Reinforcin...

Expected Impact:FOR ALL THREE THEMATIC PRIORITIES:Expected impact at the closure of the project (non-exhaustive list):Creation of new value chains in less developed regions and transition regions;Application and deployment of innovative technologies and solutions (new tothe region) in less developed and transition regions (innovation diffusion);Exploitation of project results;Innovative technologies tested and adopted by the market;Innovative solutions deployed improving businesses confidence, competencesand means to digitalise and grow;Contribution to digitisation and health systems transformation, through varioustypes of innovation and the supply of IT services;Uptake of technologically/economically reliable and viable solutions on themarket;Deployment of new technologies fostering the growth of Europe’s manufacturing sector;Innovative technologies adopted by SMEs;Identification of pos...

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated mid-phase clinical trials of natural products(i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. All applications submitted under this NOFO must be supported by sufficient preliminary data demonstrating bioavailability (if applicable) and documentation that the natural product produces a reproducible and measurable impact on target engagement (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure target engagement in the patient population of interest or when there is a fundamental understanding of the products mechanism of action will this preliminary data requirement be waived. Applications submitted to this NOFO should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site efficacy trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy trial. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mi...

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, probiotics, and products marketed as dietary supplements), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a specified target measure. If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on target engagement(s) when used by humans and assess whether there is an association between the degree of the impact on the target engagement and clinical outcomes in a participant population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the target engagement by optimizing the delivery of the natural product through exami...